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Abstract 40 
41 
The 9-valent Human Papillomavirus (HPV) vaccine, 9vHPV, was licensed in the U.S. in December, 2014. 42 
We assessed healthcare provider (HCP) awareness of the newly approved vaccine and identified 43 
questions HCPs have about the vaccine.  As part of a larger study, we used semi-structured interviews to 44 
ask 22 pediatric HCPs about their awareness of 9vHPV, questions they have about the vaccine, and 45 
questions they anticipate from patients and parents. Interviews were audio-recorded and transcribed 46 
then analyzed using inductive content analysis. Over half were aware of the vaccine but few HCPs 47 
claimed to be familiar with it. HCPs indicated several questions with common themes pertaining to 48 
efficacy, side effects, and cost. Only half of HCPs believed patients or parents would have questions. The 49 
results suggest strategies and areas for health systems and public health organizations to target in order 50 
to resolve unmet educational needs among HCPs regarding 9vHPV. 51 
52 
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Introduction  56 
Human Papillomavirus (HPV) is the most common sexually transmitted infection in the U.S.[1] HPV 57 
Infection is a risk factor for genital warts, cervical cancer, anal cancer, penile cancer, and oropharyngeal 58 
cancers. In the U.S. an estimated 360,000 people will be diagnosed with genital warts, 12,000 women 59 
will be diagnosed with cervical cancer, and over 4,000 will die from cervical cancer this year [1, 2].  60 
 61 
Currently, there are three vaccines for HPV prevention.  The bivalent vaccine, 2vHPV, protects against 62 
HPV types 16 and 18, which are responsible for about 70% of cervical cancers[3]. The quadrivalent 63 
vaccine, 4vHPV, also protects against HPV-16 and 18, as well as HPV-6 and 11, the two types that cause 64 
about 90% of genital warts [3]. At the end of 2014, the U.S Food and Drug Administration approved a 65 
nine-valent vaccine (9vHPV) that protects against the four HPV types in 4vHPV as well as five additional 66 
oncogenic types. 9vHPV has the potential to prevent up to 90% of cervical cancers, and many vulvar, 67 
vaginal, and anal cancers as well as 90% of genital warts [4]. 68 
 69 
2vHPV is licensed for females ages 9-26 and 4vHPV is licensed for males and females ages 9-26. 9vHPV is 70 
licensed for females ages 9-26 and males age 9-15 [5]. The Advisory Committee on Immunization 71 
Practices (ACIP) recommends routine vaccination for boys and girls ages 11-12 and catch up vaccination 72 
for women through age 26, men up through age 21, and for men who have sex with men or are 73 
immunocompromised through age 26 [6]. In February, 2015 ACIP issued the same age-based 74 
recommendations for 9vHPV as it did for 4vHPV [7]. ACIP further stated that if a patient returns for the 75 
second or third dose and the first dose HPV vaccine product is not available, any available HPV vaccine 76 
can be used to continue or complete the series[7].  77 
 78 
Despite the substantial benefits of being immunized, vaccination rates remain unacceptably low in the 79 
U.S. In 2014, only 60.0% of adolescent girls and 41.7% of adolescent boys ages 13 through 17 received 80 
one or more doses of HPV vaccine[8]. Given the already low uptake, implementation of a new HPV 81 
vaccine (i.e., 9vHPV) could further complicate administration processes, thereby keeping uptake low. 82 
Therefore it is important to examine provider knowledge and attitudes regarding HPV vaccination and 83 
administration processes to maximally support uptake and, as a result, population health. 84 
85 
Healthcare provider (HCP) recommendation is one of the strongest predictors of vaccine uptake [9-11]. 86 
Furthermore, a lack of HCP recommendation is a primary reason for non-vaccination [12, 13]. The 87 
purpose of this study was to assess early HCP awareness of 9vHPV as well as identify questions HCPs 88 
might have regarding 9vHPV. It is important to ascertain provider knowledge, especially given the 89 
interchangeability of 4vHPV and 9vHPV in the ACIP recommendations and the confusion this may cause 90 
in conjunction with the introduction of the new vaccine. Additionally, we wanted to ascertain any 91 
questions HCPs anticipate from parents and patients in order to assist them in addressing patient 92 
concerns. 93 
94 
Materials and methods 95 
96 
We conducted semi-structured in-person qualitative interviews from January to March, 2015. 97 
Qualitative methodology is ideal when exploring an area where little is known because it allows the 98 
investigators to identify, via in-depth analysis, relevant personal and contextual factors [14]. Participants 99 
were recruited from five urban community pediatric clinics in the Eskenazi Health System, which serves 100 
predominantly low-income patients in the Indianapolis area. Over 70% of this pediatric patient 101 
population is on Medicaid. 102 
Interviews lasted 15-30 minutes, and participants were compensated with a gift card. Interview 103 
questions about 9vHPV centered on vaccine awareness, anticipated patient and parent questions, and 104 
general questions regarding the vaccine. Twenty-nine HCPs were eligible to be interviewed and 22 105 
consented and completed the interview. Participants were recruited until saturation was reached, i.e., 106 
we were acquiring no new information from the interviews [15]. Interviews were digitally recorded then 107 
transcribed. Qualitative analysis was performed using inductive content analysis [16]. Transcripts of the 108 
interviews were read to identify meaningful themes, then two investigators independently coded each 109 
interview according to those themes. The codes were reviewed and areas of disagreement were 110 
resolved through discussion.  The study was approved by the Institutional Review Board of Indiana 111 
University (Study No. 1408987170).  112 
 113 
Results  114 
Healthcare Provider 9vHPV Awareness  115 
The sample consisted of 21 pediatricians and one pediatric nurse practitioner. They were mostly female 116 
(n=17) and averaged 14.1 years in practice. Twelve had heard of 9vHPV but six of these indicated they 117 
did not know much about it. Eight participants indicated they had not heard of 9vHPV and 2 stated they 118 
had “heard a rumor” but that they did not know much about it. For themes and exemplar quotes, see 119 
Table 1. 120 
 121 
HCP Questions 122 
When the HCPs were asked what questions they have about 9vHPV, they indicated they would like to 123 
know more about efficacy (n=7), side effects (n=6), added protection over 4vHPV (n=5), dosing schedule 124 
(n=5), cost (n=5), and safety (n=4). Some HCPs indicated that they would like general information either 125 
for their own knowledge or to help them answer questions from patients or parents (n=5). Additionally, 126 
four providers wanted to know when it would be available. 127 
128 
Anticipated Parent and Patient Questions 129 
Twenty-one of the HCPs were asked if they thought patients or parents would have questions about 130 
9vHPV. Eleven said they did not think they would have any questions at all. When asked why, four 131 
indicated they did not think patients or parents would have questions beyond those they already have 132 
had about 4vHPV. These HCPs also noted that there were not any additional questions for the 133 
pneumococcal vaccine when it went from 7-valent to 13-valent. Furthermore, three indicated that 134 
patients do not understand the science behind vaccines enough to know the difference between 135 
valencies and therefore would not have any additional questions.  136 
137 
Interestingly, although the majority of HCPs indicated they did not expect questions about 9vHPV, most 138 
did go on to list possible questions patients might have. HCPs anticipated questions regarding side 139 
effects (n=9), effectiveness (n=3), and safety (n=3). Some thought parents would want to know if the 140 
new vaccine was really necessary or better than 4vHPV (n=5). Four of the HCPs (19%) thought that their 141 
patients would want long-term data due to perceived lack of real world experience with the new vaccine 142 
(see Table 1). 143 
144 
Discussion 145 
HCP recommendation is one of the strongest predictors of HPV vaccine uptake. In this sample, just over 146 
half of HCPs were aware of the 9vHPV vaccine. Increasing HCP awareness of the licensing and 147 
recommendations for 9vHPV will be pivotal in increasing vaccine uptake. HCPs had questions about the 148 
vaccine mainly regarding efficacy, safety, side effects, cost, and dosing schedule. While the results 149 
indicate there is a need to increase HCP awareness, it is likely that as 9vHPV becomes more readily 150 
available, HCPs will become more aware of the vaccine through marketing and educational campaigns.  151 
 152 
Most HCPs did not anticipate that parents or patients would have questions about 9vHPV.  This finding is 153 
particularly interesting in light of a recent study by Fontenot et al. which found that parents had many 154 
questions about 9vHPV, including concerns about safety and whether yet another HPV vaccine might be 155 
developed in the near future [17]. However, the differences between what the providers in this study 156 
anticipated and what Fontenot et al. found could be due to different patient populations. The majority 157 
of participants in the Fontenot study were married, employed full time, and had at least some college 158 
education whereas the providers in this study serve economically disadvantaged populations. However, 159 
it is reasonable to infer that parents will have questions about a new HPV vaccine, given the negative 160 
media attention that arose with the first generation HPV vaccines [18, 19]. HCPs who did anticipate 161 
questions indicated there would potentially be questions from parents and patients regarding side 162 
effects, safety, effectiveness, and necessity of the vaccine. Now that 9vHPV is licensed and 163 
recommended, these results indicate a need to increase awareness and knowledge among HCPs. Given 164 
that physicians continue to hold misconceptions about 4vHPV, it will be particularly important to 165 
address areas of awareness and education regarding 9vHPV [20]. Additionally, there are unmet 166 
educational needs among HCPs regarding the new vaccine, specifically regarding safety, side effects, and 167 
efficacy. Furthermore, HCPs may also need assistance in anticipating and addressing patient questions. 168 
 169 
This study is among the first to assess HCP awareness and questions regarding 9vHPV, but it has 170 
limitations.  Participants were a convenience sample of HCPs in a health system that generally serves 171 
minority and economically disadvantaged patients, so responses may not be representative of the 172 
broader experiences of HCPs. Selection bias might have occurred and the HCPs who agreed to 173 
participate might have different attitudes about vaccination than the participants who did not respond 174 
to recruitment e-mails. 175 
176 
Conclusions 177 
HCPs have unmet educational needs regarding 9vHPV. HCPs need educational tools to anticipate and 178 
answer questions from parents and patients. To our knowledge, this is the first study to assess HCP 179 
awareness of 9vHPV licensing as well as questions HCPs have about the vaccine. Awareness of 180 
information deficits can help health systems and public health agencies create and target educational 181 
materials to provide information on the efficacy and safety of the new 9vHPV. 182 
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Concept Theme Exemplar Quotes 
HPV Vaccine Awareness 
Aware (n=12) “I’ve heard of it but I haven’t gotten a lot of literature about it.” 
“Yes. Can't wait for it to come to my clinics.” 
Does not know much (n=6) “I might have heard something about it, but I am not terribly familiar with it.” 
“I have [heard of HPV9], but honestly I don’t know that much about it.” 
Unaware (n=8) “No.  But honestly I don’t even know what the current one is.” 
“I don’t think I’ve heard about anything new regarding any sort of HPV vaccine.” 
Heard a Rumor (n=2) “Vaguely, yes, I’ve heard rumors” 
HCP Questions 
Efficacy (n=7) “Just as long as it’s equally efficacious and I believe it is.” 
Side Effects (n=6) “Just the adverse side effects for my patients and making sure that they’re knowledgeable 
about it.” 
Additional Protection (n=5) “How much more coverage do you get against all the different types of HPV that cause 
cervical cancer?” 
Dosing Schedule (n=5) “Do you have any idea what the recommended dosing schedule for that one is; is it also 
three vaccinations?” 
Cost (n=5) “I'm waiting to see the degree at which cost will impact its availability, so whether that's 
going to affect our ability to stock it in clinic or whether patients will have the differential 
coverage for it from their insurers based on whether they're getting the Quadrivalent or 
Nanovalent.” 
General Information (n=5) “I just want to look at that information myself.  I just haven’t done it yet.” 
“I don’t feel like I know a lot about it right now, so I think that would be the main thing is 
just getting informed about it.” 
Safety (n=4) “I guess with vaccines you always -- as a provider when you’re counseling people on it, you 
want to make sure you know about safety, side effects, everything.” 
Anticipated 
parent/patient questions 
Parents will not have 
questions (n=11) 
“No I don’t think so.  I think that they trust in me so that if recommend a vaccine that they 
know that it is something that their child needs.” 
No more than HPV4 
questions (n=4) 
R:  “I don’t know that the 9-valent will have any more questions by parents.” 
INT:  “As opposed…as compared to the quadrivalent?” 
R:  “Yes.”   
“I don't think it's going to bring up any new questions because it's not a totally new 
vaccine.  It's the same vaccine, just more parts to it because nothing really happened when 
we switched from 7 to 13 on the pneumococcal.  Nobody questions it.” 
Lack of scientific 
understanding (n=3) 
“No. I think for my clinic population I would say no.  That’s just based on other vaccine 
modifications that haven’t spurred any increase in questions about the strains.  I got a lot 
Tables
more questions about Thimerosal and whether that’s included versus like the actual, 
what’s included in the vaccine from a scientific standpoint, if that makes any sense.”  
Anticipated Questions 
Side Effects (n=9) “If there’s any side-effects to worry about.  That’s usually the biggest one.” 
Safety (n=3) “I think parents are more concerned about safety than they are even about efficacy and 
what it prevents and how helpful it is.” 
Effectiveness (n=3) “I think they’d have the same questions [as the physician], like does it -- how well does it 
work and what are the side effects, how safe is it?” 
Necessity of Vaccination 
(n=5) 
“They’ll want to know about how—some of them will ask how long has it been given?  Is it 
necessary?  Is it better?  Is it—that kind of thing.” 
Long-term Data  (n=4) “Probably the same in regards to what would happen if they take this vaccination and 
potentially what would happen in the next five years after receiving it.” 
